Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)

NCT05836259 is registered in ClinicalTrials.gov with Tenaya Therapeutics as lead sponsor.

NCT NCT05836259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05836259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)
Lead sponsor
Tenaya Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 10, 2023
Completion date
August 31, 2032
Enrollment
30 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hypertrophic cardiomyopathy